{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:38:37Z","timestamp":1782830317874,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.ijantimicag.2023.106746","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T18:36:50Z","timestamp":1675881410000},"page":"106746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI"],"prefix":"10.1016","volume":"61","author":[{"given":"Theodossis","family":"Papavramidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Magnasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Francisci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamantis P.","family":"Kofteridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3884-4933","authenticated-orcid":false,"given":"Giusy","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J.","family":"Giamarellos-Bourboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0148-1075","authenticated-orcid":false,"given":"Simone Mornese","family":"Pinna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"La Ferla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Periklis","family":"Panagopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Gattuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos V.","family":"Sipsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Corio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Comandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0570-9903","authenticated-orcid":false,"given":"Patrizia","family":"Mascagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106746_bib0001","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2023.106746_bib0002","unstructured":"Food and Drug Administration. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment (2013)."},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2023.106746_bib0003","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1198-743X(16)30095-7","article-title":"Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections","volume":"22","author":"Russo","year":"2016","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2023.106746_bib0004","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/S0924-8579(09)70544-8","article-title":"Why is community-associated MRSA spreading across the world and how will it change clinical practice?","volume":"34","author":"Bassetti","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106746_bib0005","series-title":"European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2020. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","year":"2022"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106746_bib0006","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijantimicag.2019.08.020","article-title":"Microbiology of acute bacterial skin and skin-structure infections in Greece: A proposed clinical prediction score for the causative pathogen","volume":"54","author":"Nodaras","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106746_bib0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/1120009X.2017.1311398","article-title":"Diagnosis and management of skin and soft-tissue infections (SSTI). A literature review and consensus statement: an update","volume":"29","author":"Esposito","year":"2017","journal-title":"J Chemother"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106746_bib0008","first-page":"143","article-title":"Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure","volume":"4","author":"Pulido-Cejudo","year":"2017","journal-title":"Ther Adv Infect Dis"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106746_bib0009","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106746_bib0010","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106746_bib0011","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/422147","article-title":"Causal relationship between neuropathy and prolonged linezolid use","volume":"39","author":"Frippiat","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106746_bib0012","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/11597460-000000000-00000","article-title":"Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports","volume":"35","author":"Kim","year":"2012","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106746_bib0013","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106746_bib0014","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijantimicag.2015.07.022","article-title":"Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus from invasive infections","volume":"46","author":"Decousser","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106746_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13756-016-0131-6","article-title":"Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantation","volume":"5","author":"Krull","year":"2016","journal-title":"Antimicrob Resist Infect Control"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106746_bib0016","first-page":"269","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J Biol Med"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106746_bib0017","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/AAC.02626-15","article-title":"Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with Staphylococcus aureus skin infections","volume":"60","author":"Eells","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106746_bib0018","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.annemergmed.2007.12.004","article-title":"Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus","volume":"51","author":"Pallin","year":"2008","journal-title":"Ann Emerg Med"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106746_bib0019","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cid\/ciu410","article-title":"Staphylococcus aureus bacteremia at five U.S. Academic Medical Centers, 2008\u20132011: significant geographic variation in community-onset infections","volume":"59","author":"David","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2023.106746_bib0020","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/ciz004","article-title":"Current treatment options for acute skin and skin-structure infections","volume":"68","author":"Golan","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106746_bib0021","unstructured":"US Food and Drug Administration (FDA). DALVANCETM highlights of prescribing information. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021883s000lbl.pdf. [Accessed 1 April 2017]."},{"key":"10.1016\/j.ijantimicag.2023.106746_bib0022","unstructured":"European Medicines Agency (EMA). Xydalba summary of product characteristics. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/002840\/WC500183869.pdf. [Accessed 1April 2017]."},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106746_bib0023","first-page":"313","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infections","volume":"23","author":"Esposito","year":"2015","journal-title":"Infez Med"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106746_bib0024","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1128\/AAC.48.3.940-945.2004","article-title":"Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers","volume":"48","author":"Leighton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2023.106746_bib0025","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/jac\/dki008","article-title":"Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide","volume":"55","author":"Dorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106746_bib0026","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ijantimicag.2023.106746_bib0027","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1086\/379015","article-title":"Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections","volume":"37","author":"Seltzer","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ijantimicag.2023.106746_bib0028","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/497271","article-title":"Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections","volume":"41","author":"Jauregui","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106746_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106503","article-title":"Update on activity of dalbavancin and comparators against clinical isolates of Gram-positive pathogens from Europe and Russia (2017-2018), and on clonal distribution of MRSA","volume":"59","author":"Riccobono","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106746_bib0030","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s10096-019-03609-9","article-title":"Early discharge criteria in patients with acute bacterial skin and skin structure infections in a large tertiary-care teaching hospital in Florence, Italy","volume":"38","author":"Lagi","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106746_bib0031","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhin.2017.01.017","article-title":"Landmark prediction of nosocomial infection risk to disentangle short- and long-stay patients","volume":"96","author":"Wolkewitz","year":"2017","journal-title":"J Hosp Infect"},{"issue":"12","key":"10.1016\/j.ijantimicag.2023.106746_bib0032","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1080\/14787210.2020.1798227","article-title":"Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study)","volume":"18","author":"Bai","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106746_bib0033","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: The ENHANCE Trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect Dis Ther"},{"issue":"11","key":"10.1016\/j.ijantimicag.2023.106746_bib0034","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/antibiotics10111296","article-title":"Comparative analysis of dalbavancin versus other antimicrobial options for gram-positive cocci infections: effectiveness, hospital stay and mortality","volume":"10","author":"De Pablo-Mir\u00f3","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106746_bib0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings","volume":"54","author":"Streifel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106746_bib0036","first-page":"45","article-title":"Analisi di minimizzazione dei costi del trattamento delle infezioni batteriche acute di cute e struttura cutanea a livello del sito chirurgico in pazienti sottoposti ad intervento cardiochirurgico","volume":"3","author":"Barbieri","year":"2016","journal-title":"HTA Focus"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923000341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:30Z","timestamp":1760377530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923000341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0924857923000341"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106746","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106746","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106746"}}